Anticancer Platinum Drugs Update

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2021 Nov 27

PMID 34827636

Citations 6

Authors

Giuliano Ciarimboli

Affiliations

Soon will be listed here.

Abstract

The discovery of the anticancer properties of platinum derivatives by Rosenberg represents a milestone in the development of chemotherapeutic protocols for tumor treatment [...].

Citing Articles

Novel Pt (II) Complexes With Anticancer Activity Against Pancreatic Ductal Adenocarcinoma Cells.

Stefano E, Rovito G, Cossa L, Castro F, Vergaro V, Ali A Bioinorg Chem Appl. 2025; 2024:5588491.

PMID: 39886428 PMC: 11779987. DOI: 10.1155/bca/5588491.

Platinum-based chemotherapies-induced nephrotoxicity: mechanisms, potential treatments, and management.

Shahrahmani F, Badamchizadeh S, Kaihani F, Alavi-Moghadam S, Keshtkari S, Rezaei-Tavirani M Int Urol Nephrol. 2024; .

PMID: 39630371 DOI: 10.1007/s11255-024-04303-2.

Protective effect of lyophilized extract against carboplatin-induced liver injury via inhibition of oxidative stress and inflammation in rats.

Nwadibia J, Fasogbon I, Musyoka A, Ekpono E, Ibiam U, Orji O Toxicol Rep. 2024; 13:101734.

PMID: 39328341 PMC: 11426155. DOI: 10.1016/j.toxrep.2024.101734.

Biological Mediators and Partial Regulatory Mechanisms on Neuropathic Pain Associated With Chemotherapeutic Agents.

Liu Z, Liu S, Zhao Y, Wang Q Physiol Res. 2024; 73(3):333-341.

PMID: 39027951 PMC: 11299781. DOI: 10.33549/physiolres.935162.

KYNU Expression Promotes Cisplatin Resistance in Esophageal Cancer.

Lu Y, Zhao X, Yuan M, Zhao M, Liu K, Zhang M J Cancer. 2024; 15(9):2475-2485.

PMID: 38577600 PMC: 10988315. DOI: 10.7150/jca.93229.

References

Nejad M, Urbassek H . Adsorption and Diffusion of Cisplatin Molecules in Nanoporous Materials: A Molecular Dynamics Study. Biomolecules. 2019; 9(5). PMC: 6572581. DOI: 10.3390/biom9050204. View

Lanvers-Kaminsky C, Sprowl J, Malath I, Deuster D, Eveslage M, Schlatter E . Human OCT2 variant c.808G>T confers protection effect against cisplatin-induced ototoxicity. Pharmacogenomics. 2015; 16(4):323-32. PMC: 4865798. DOI: 10.2217/pgs.14.182. View

Rebe C, Demontoux L, Pilot T, Ghiringhelli F . Platinum Derivatives Effects on Anticancer Immune Response. Biomolecules. 2019; 10(1). PMC: 7022223. DOI: 10.3390/biom10010013. View

Rosenberg B, VANCAMP L, Trosko J, Mansour V . Platinum compounds: a new class of potent antitumour agents. Nature. 1969; 222(5191):385-6. DOI: 10.1038/222385a0. View

Rottenberg S, Disler C, Perego P . The rediscovery of platinum-based cancer therapy. Nat Rev Cancer. 2020; 21(1):37-50. DOI: 10.1038/s41568-020-00308-y. View

Antonaci G, Cossa L, Muscella A, Vetrugno C, De Pascali S, Fanizzi F . [Pt('-acac)(γ-acac)(DMS)] Induces Autophagy in Caki-1 Renal Cancer Cells. Biomolecules. 2019; 9(3). PMC: 6468382. DOI: 10.3390/biom9030092. View

Frenzel D, Koppen C, Bauer O, Karst U, Schroter R, Tzvetkov M . Effects of Single Nucleotide Polymorphism Ala270Ser (rs316019) on the Function and Regulation of hOCT2. Biomolecules. 2019; 9(10). PMC: 6843571. DOI: 10.3390/biom9100578. View

Ciarimboli G, Deuster D, Knief A, Sperling M, Holtkamp M, Edemir B . Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions. Am J Pathol. 2010; 176(3):1169-80. PMC: 2832140. DOI: 10.2353/ajpath.2010.090610. View

Nguyen D, Bach L, Nguyen Tran D, Cao V, Nguyen T, Le T . Partial Surface Modification of Low Generation Polyamidoamine Dendrimers: Gaining Insight into their Potential for Improved Carboplatin Delivery. Biomolecules. 2019; 9(6). PMC: 6627870. DOI: 10.3390/biom9060214. View

10.

Sprowl J, Ciarimboli G, Lancaster C, Giovinazzo H, Gibson A, Du G . Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2. Proc Natl Acad Sci U S A. 2013; 110(27):11199-204. PMC: 3704038. DOI: 10.1073/pnas.1305321110. View

11.

Einhorn L . Curing metastatic testicular cancer. Proc Natl Acad Sci U S A. 2002; 99(7):4592-5. PMC: 123692. DOI: 10.1073/pnas.072067999. View

12.

Hato S, Khong A, de Vries I, Lesterhuis W . Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics. Clin Cancer Res. 2014; 20(11):2831-7. DOI: 10.1158/1078-0432.CCR-13-3141. View

13.

Oun R, Moussa Y, Wheate N . The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton Trans. 2018; 47(19):6645-6653. DOI: 10.1039/c8dt00838h. View

14.

Rosenberg B, VANCAMP L . The successful regression of large solid sarcoma 180 tumors by platinum compounds. Cancer Res. 1970; 30(6):1799-802. View

15.

Rosenberg B . Platinum coordination complexes in cancer chemotherapy. Naturwissenschaften. 1973; 60(9):399-406. DOI: 10.1007/BF00623551. View

16.

Varbanov H, Kuttler F, Banfi D, Turcatti G, Dyson P . Screening-based approach to discover effective platinum-based chemotherapies for cancers with poor prognosis. PLoS One. 2019; 14(1):e0211268. PMC: 6350982. DOI: 10.1371/journal.pone.0211268. View

17.

Ciarimboli G, Ludwig T, Lang D, Pavenstadt H, Koepsell H, Piechota H . Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol. 2005; 167(6):1477-84. PMC: 1613191. DOI: 10.1016/S0002-9440(10)61234-5. View